A Phase II, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine

Trial Profile

A Phase II, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2011

At a glance

  • Drugs Talmapimod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SPRiNG
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2010 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top